Published in Cancer Weekly, December 31st, 2002
"Until recently," they said, "this therapeutic strategy has been used as a single specific treatment and clinical studies have demonstrated that tumor-specific T-cell responses can be induced in a subset of patients and even in patients with advanced disease. However, it remains to be demonstrated whether these T-cell responses can mediate clinically relevant antitumor reactivity."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.